Lenvatinib shows promise for patients with radioiodine-refractory thyroid cancer

In a pivotal Phase III study the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1EyseEo